Empagliflozin is associated with lower risk of cardiovascular events and all ‐cause mortality in routine care in East Asia: Results from the EMPRISE study

ConclusionsThe results suggest that both empagliflozin and SGLT2i compared with DPP-4i are associated with a lower risk of cardiovascular events and all-cause mortality in routine clinical care in East Asia.

Source: Journal of Diabetes Investigation - January 31, 2023 Category: Endocrinology Authors: Dae Jung Kim, Wayne H ‐H Sheu, Wook‐Jin Chung, Daisuke Yabe, Kyoung Hwa Ha, Masaomi Nangaku, Elise Chia‐Hui Tan, Koichi Node, Atsutaka Yasui, Weiyu Lei, Sunwoo Lee, Laura Saarelainen, Anouk Deruaz‐Luyet, Moe H Kyaw, Yutaka Seino, EM Tags: ORIGINAL ARTICLE Source Type: research